The U.S. government wants to sign an exclusive deal with French pharma giant Sanofi to further develop and roll out a new vaccine that could help halt the spread of Zika. NGOs, including MSF, think the vaccine technology, which was developed using tax payers' money, should be shared with other companies too and argue this will ensure the vaccine gets developed faster and is made affordable to people in middle-income and developing countries. Sign in or join Devex to read the rest Not only will you get to finish this article, you will also unlock access to community content from our global team of journalists covering the latest global health, humanitarian aid and international development news. And it's totally free. Join usSign in

Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro subscribers may share up to 10 articles per month using the Pro share tool ( ).